ClinicalTrials.gg
RecruitingNCT05911711Updated Jun 22, 2023

Identification and Clinical Efficacy Analysis of Biomarkers in Sepsis Patients

An observational study in Sepsis, sponsored by Kangdong Sacred Heart Hospital. Recruiting at 1 site in Korea, Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-22.

Sponsored by Kangdong Sacred Heart Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 10 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
120
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Sepsis with a site in Korea, Republic of — 9 open to participants now, 9 under way, none of them phase 3. Sepsis · Korea, Republic of.

Planned enrollment
9th of 11
120 · median 245
Started
2023
with 1 other
Observational
11 of 31
7 open now
Registered
25th of 31
by date

Among the 31 studies in Sepsis with a site in Korea, Republic of, this one is the 9th largest by planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2023, is one of 11 observational ones, and was the 25th registered.

Sepsis

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

9 of the 31 studies in Sepsis with a site in Korea, Republic of are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Sepsis with a site in Korea, Republic of, or all of them as a file.
02

Study summary

Sepsis, a severe response to bacterial infection, lacks understanding of immunometabolic features that can identify high-risk patients. This study aimed to discover immune, biological, and metabolic biomarkers in sepsis patients with poor prognosis and understand the underlying mechanisms of host immune responses.

Read the detailed description

Sepsis is a life-threatening condition resulting from a dysregulated host response to infection and remains a significant global health crisis. Accurately identifying high-risk patients and understanding the underlying mechanisms of distinct host responses are crucial. Dysregulation of immune and biological responses, along with metabolic remodeling, has emerged as a prevalent characteristic in sepsis patients. However, there is still a need for a comprehensive understanding of specific markers related to immunometabolism and the underlying mechanisms contributing to the disturbance in sepsis pathogenesis.

This study aims to investigate the immune, biological, and metabolic profiles of sepsis patients, focusing on the alteration of metabolism in sepsis patients with poor outcomes. The findings of this study will provide valuable insights into dysregulated immunometabolism, shedding light on its contribution to the potentiation of immunopathogenesis in sepsis.

Eligibility Criteria adults over the age of 19 a sepsis patient in ICU

Patients are excluded from the study If the patient or care giver does not agree to participate in the study a bone marrow transplant or an organ transplant patient a Do not resuscitation(DNR) patient a patient under the age of 18

Outcome Measure ICU mortality, 28 days mortality Use of inotropics, vasopressors CRRT(continuous renal replacement therapy), ECMO (Extracorporeal membrane oxygenation), Interventional lung assist, polymyxin

03

Conditions studied

  • Sepsis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

sepsis patient in Medical ICU sepsis definition : Sepsis is life-threatening organ dysfunction caused by a dysregulated host response to infection

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adults over the age of 19 a sepsis patient in ICU

Exclusion criteria

Exclusion Criteria:

  • If the patient or care giver does not agree to participate in the study a bone marrow transplant or an organ transplant patient a DNR patient a patient under the age of 18
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
120 participants (estimated)
Target follow-up
28 Days
Patient registry
Yes
Biospecimen retention
Samples without dna

Groups and cohorts

  • Sepsis patient in Medical ICU

    Eligibility Criteria: adults over the age of 19 a sepsis patient in Medical ICU Patients are excluded from the study : If the patient or care giver does not agree to participate in the study a bone marrow transplant or an organ transplant patient a Do not resuscitation (DNR) patient

    Other: Prognostic factor

Interventions

  • OtherPrognostic factor

    normal person (no sepsis group)

06

What researchers measure

Primary outcomes

  1. up to 1 day ICU mortality"

    up to 1 day ICU mortality"

    Time frame: up to 1 day ICU mortality"

Secondary outcomes

  1. 28 days mortality

    28 days mortality

    Time frame: 28 days mortality

07

Study locations

1 of 1 sites recruiting
  • KangdonSHH
    Seoul, 05355, Korea, Republic of
    Recruiting
08

References and documents

Publications

  • Park SY, Shrestha S, Youn YJ, Kim JK, Kim SY, Kim HJ, Park SH, Ahn WG, Kim S, Lee MG, Jung KS, Park YB, Mo EK, Ko Y, Lee SY, Koh Y, Park MJ, Song DK, Hong CW. Autophagy Primes Neutrophils for Neutrophil Extracellular Trap Formation during Sepsis. Am J Respir Crit Care Med. 2017 Sep 1;196(5):577-589. doi: 10.1164/rccm.201603-0596OC. PubMed 28358992 ↗

Individual participant data

Plan to share: Yes — This study complies with the Helsinki Declaration, is conducted in accordance with the test plan approved by the Institutional Bioethics Committee (IRB) of Kangdong Sacred Heart Hospital, and will be conducted in accordance with the clinical trial management standards (GCP) set by the Korea Food and Drug Administration. Personal information is not included in the research results, and for this purpose, personal information will not be included even when the research results are published and the research results are disclosed by assigning a code number to the research results. Clinical Information Analysis reviews patient's charts and the lead researcher is responsible for the supervision of the state to ensure that personal information collected before being coded is not leaked.

Supporting information: Informed consent form

Time frame: Keeping research-related records for three years from the time the research is completed pursuant to Article 15 of the Enforcement Rule of the Bioethics and Safety Act

Access criteria: adults over the age of 19 a sepsis patient in Medical ICU

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2023; primary completion for Dec 2023, 5 months later.

Of 496 non-industry observational studies under Sepsis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 57. This study's planned 5 months is below that.

Counting every sponsor, half of 548 studies reached it within 27 months; a quarter within 12 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2023
First posted
Jun 22, 2023
StartEst.
Jul 7, 2023
Primary completionEst.
Dec 31, 2023
CompletionEst.
Jun 7, 2024
Last update
Jun 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05911711
Lead sponsor
Kangdong Sacred Heart Hospital
Collaborators
Chungnam National University, Chungnam National University Hospital
Responsible party
So Young Park (associate professor, Kangdong Sacred Heart Hospital) — Principal investigator
First posted
Jun 22, 2023
Start date
Jul 7, 2023 (estimated)
Primary completion
Dec 31, 2023 (estimated)
Completion
Jun 7, 2024 (estimated)
Last update
Jun 22, 2023

Study contacts

So Young Park, doctor
Contact
sy.park12@gmail.com
+8201052058637 ext. KangdongSHH
Eun-Kyeong Jo, doctor
Contact
hayoungj@cnu.ac.kr
+8201047628243
So Young Park, doctor
study chair · Kangdong Sacred Heart Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion